Compare Annaly Capital Management, Inc. (NLY) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

NLY trades at $17.93, down 2.66% on the day, amid a bearish technical signal despite a low P/E of 4.33 and P/B of 0.89 suggesting undervaluation. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending. Strong profitability metrics include a net income margin of 92.77% and ROE of 20.66%. Recent news highlights its high dividend yield near 15% and portfolio expansion, though the stock faces pressure from rising mortgage rates and a negative cash flow from investing activities of -$27.36 billion in 2025.

The outlook is mixed: attractive valuation and consistent earnings beats support upside to the $22.00 consensus price target, but high leverage (debt-to-asset ratio of 23.55 in 2025) and interest rate sensitivity pose significant risks. Investors are compensated with a robust dividend, yet the stock's recent decline reflects concerns over macroeconomic headwinds impacting mortgage REITs.

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.